Showing 1041-1050 of 5062 results for "".
- Upadacitinib Meets Primary Endpoint in Two Phase 3 Alopecia Areata Trialshttps://practicaldermatology.com/news/upadacitinib-meets-primary-endpoint-in-two-phase-3-alopecia-areata-trials/2488081/New data suggests upadacitinib was associated with significantly greater scalp hair regrowth than placebo among adults and adolescents with severe alopecia areata (AA), according to findings published online August 12 in JAMA Dermatology. The replicate UP-AA1 and UP-AA2 trials enr
- D-2570 Shows High PASI Response Rates in Phase 2 Psoriasis Studyhttps://practicaldermatology.com/news/d-2570-shows-high-pasi-response-rates-in-phase-2-psoriasis-study/2488078/A novel oral TYK2 inhibitor produced significantly higher skin clearance rates than placebo in patients with moderate-to-severe plaque psoriasis, according to research published in Journal of the American Academy of Dermatology. D-2570 is a TYK2 inhibitor under development for aut
- Fractional CO₂ Laser-Assisted Methotrexate Rivals 5-FU in Stable Vitiligohttps://practicaldermatology.com/news/fractional-co-laser-assisted-methotrexate-rivals-5-fu-in-stable-vitiligo/2487990/Topical methotrexate (MTX) delivered through fractional CO₂ laser (FCL) demonstrated efficacy and safety comparable to laser-assisted 5-fluorouracil (5-FU) for stable, nonsegmental vitiligo, according to a study published in Derm
- Study: Anumigilimab Well Tolerated in HS and Palmoplantar Pustulosishttps://practicaldermatology.com/news/study-anumigilimab-well-tolerated-in-hs-and-palmoplantar-pustulosis/2487876/Anumigilimab was generally well tolerated in patients with hidradenitis suppurativa (HS) or palmoplantar pustulosis (PPP), while providing preliminary signals of clinical activity in both neutrophil-driven inflammatory skin diseases, results from a Phase 1b study
- Skin Cancer Champions Earns Two Digital Health Awards for Patient Education and Community Engagementhttps://practicaldermatology.com/news/skin-cancer-champions-earns-two-digital-health-awards-for-patient-education-and-community-engagement/2487580/Skin Cancer Champions, an online community dedicated to supporting patients and caregivers affected by non-melanoma skin cancers, has received two Bronze Awards in the Spring 2026 Digital Health Awards, presented by the Health Information Resource Center (HIRC). The awards recognize the or
- Intermittent Daily Isotretinoin Matches Alternate-Day Regimen in Grade 2 Acne Trialhttps://practicaldermatology.com/news/intermittent-daily-isotretinoin-matches-alternate-day-regimen-in-grade-2-acne-trial/2487522/A randomized controlled trial published in the Indian Journal of Medical Research found that an intermittent daily isotretinoin regimen was non-inferior to a continuous alternate-day regimen for the treatment of grade 2 facial acne vulgaris, while also offering lower treatment costs.¹ Rese
- FDA Expands Dupilumab CSU Indication to Children as Young as 2 Yearshttps://practicaldermatology.com/news/dupilumab-approval-expanded-to-include-children-as-young-as-2-years-with-csu/2487479/The US Food and Drug Administration (FDA) has expanded the indication for dupilumab (Dupixent; Sanofi and Regeneron) to include pediatric patients aged 2 to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. The label expansion, according
- FDA Approves EBGLYSS 8-Week Dosings in Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-ebglyss-8-week-dosings-in-atopic-dermatitis/2487424/The US Food and Drug Administration (FDA) has approved an every-8-week maintenance dosing regimen for EBGLYSS® (lebrikizumab-lbkz) in adults and adolescents aged 12 years and older weighing at least 40 kg with moderate-to-severe atopic dermatitis, according to an
- SCRATCH-AD: Rapid Itch Reduction, Biomarker Improvements with Ruxolitinibhttps://practicaldermatology.com/news/scratch-ad-rapid-itch-reduction-biomarker-improvements-with-ruxolitinib/2487381/Patients with atopic dermatitis (AD) treated with ruxolitinib 1.5% cream experienced rapid and sustained reductions in itch alongside improvements in disease-associated biomarkers, according to findings from the SCRATCH-AD study. The open-label SCRATCH-AD trial (NCT04839380) evaluated the
- Study: Hair Care Regimen May Enhance Minoxidil Response in Women With Hair Losshttps://practicaldermatology.com/news/seen-study-suggests-hair-care-regimen-may-enhance-minoxidil-response-in-women-with-hair-loss/2487130/SEEN Hair Care presented new clinical findings at the 2026 Music City Symposium for Cosmetic Advances and Laser Education (SCALE), suggesting that a non-comedogenic, non-irritating hair care regimen may improve outcomes with topical minoxidil 5% foam in women with